502 related articles for article (PubMed ID: 8182940)
1. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
4. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
5. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.
Maschan AA; Kryzanovskii OI; Yourlova MI; Skorobogatova EV; Pashanov ED; Potapova YE; Timonova LA; Bogatcheva NY; Samochatova EV; Roumjantzev AG
Bone Marrow Transplant; 1997 Feb; 19(4):385-7. PubMed ID: 9051250
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Matsuyama T; Kojima S; Kato K
Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
[TBL] [Abstract][Full Text] [Related]
10. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
Urban C; Schwinger W; Slavc I; Schmid C; Gamillscheg A; Lackner H; Hauer C; Pakisch B
Bone Marrow Transplant; 1990 May; 5(5):353-6. PubMed ID: 2190661
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
12. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
13. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
[TBL] [Abstract][Full Text] [Related]
14. Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Rubie H; Attal M; Demur C; Brousset P; Duchayne E; Rigal-Huguet F; Dastugue N; Robert A
Bone Marrow Transplant; 1994 Jun; 13(6):759-62. PubMed ID: 7920311
[TBL] [Abstract][Full Text] [Related]
15. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children.
Nagatoshi Y; Okamura J; Ikuno Y; Akamatsu M; Tasaka H
Int J Hematol; 1997 Apr; 65(3):269-75. PubMed ID: 9114598
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic bone marrow transplantation for children with myelodysplastic syndrome.
Uçkan D; Cetin M; Hiçsönmez G; Tezcan I; Tuncer AM
Turk J Pediatr; 2000; 42(3):192-7. PubMed ID: 11105616
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Ratanatharathorn V; Karanes C; Lum LG; Uberti J; Dan ME; de Planque MM; Schultz KR; Cronin S; Leisz MC; Mohamed A
Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949
[TBL] [Abstract][Full Text] [Related]
20. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
